Summary for Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
This study was a nationwide, population based study in Spain that utilized two-stage random sampling stratified by province and municipality size. From April 27 to May 11, 2020, 61,075 participants (75·1% of all contacted individuals within selected households) answered a questionnaire.
Seroprevalence was 5·0% (95% CI 4·7–5·4) by the point-of-care test and 4·6% (4·3–5·0) by immunoassay. There was substantial geographical variability, with higher prevalence around Madrid (>10%) and lower in coastal areas (<3%).
In 7273 individuals with anosmia or at least three symptoms, seroprevalence ranged from 15·3% (13·8–16·8) to 19·3% (17·7–21·0). Around a third of seropositive participants were asymptomatic, ranging from 21·9% (19·1–24·9) to 35·8% (33·1–38·5). Only 19·5% (16·3–23·2) of symptomatic participants who were seropositive by both the point-of-care test and immunoassay reported a previous PCR test.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
Summary for Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study
Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium
Introduction for Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Summary for Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study
Antibody Testing in Germany
Antibody dynamics to SARS-CoV-2 in Asymptomatic and Mild COVID-19 patients
SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months
Prevalence of IgG antibodies to SARS-CoV-2 in Wuhan–implications for the ability to produce long-lasting protective antibodies against SARS-CoV-2
Diagnostic Tool for Coronavirus Being Developed by University of Warwick
Saliva could be an alternative fluid to test COVID-19 antibodies
Seroprevalence of anti-SARS-CoV-2 spike protein antibodies in the New York Metropolitan Area